Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: A pilot-study

[1]  Viswanath Devanarayan,et al.  Evaluation of Plasma Proteomic Data for Alzheimer Disease State Classification and for the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease , 2013, Alzheimer disease and associated disorders.

[2]  M. Fornage,et al.  Cardiovascular Biomarkers and Subclinical Brain Disease in the Atherosclerosis Risk in Communities Study , 2013, Stroke.

[3]  Murray Grossman,et al.  Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease , 2012, Neurology.

[4]  A. Diedrich,et al.  Influences of Donepezil on Cardiovascular System—Possible Therapeutic Benefits for Heart Failure—DOnepezil Cardiac TEst Registry (DOCTER) Study , 2012, Journal of cardiovascular pharmacology.

[5]  Christoph Laske,et al.  Identification of a blood-based biomarker panel for classification of Alzheimer's disease. , 2011, The international journal of neuropsychopharmacology.

[6]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[7]  Alan S Maisel,et al.  Elevated natriuretic peptide levels and cognitive function in community-dwelling older adults. , 2011, The American journal of medicine.

[8]  Christian Humpel,et al.  Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? , 2011, Experimental Gerontology.

[9]  K. Blennow,et al.  Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment. , 2011, The Journal of clinical psychiatry.

[10]  Georg Kemmler,et al.  Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease , 2011, Neurobiology of Aging.

[11]  Christian Humpel,et al.  Identifying and validating biomarkers for Alzheimer's disease , 2011, Trends in biotechnology.

[12]  Wendy R. Sanhai,et al.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.

[13]  K. Blennow,et al.  Amyloid β and APP as biomarkers for Alzheimer’s disease , 2010, Experimental Gerontology.

[14]  Bengt Winblad,et al.  Biomarkers for Alzheimer’s disease and other forms of dementia: Clinical needs, limitations and future aspects , 2010, Experimental Gerontology.

[15]  H. Hampel,et al.  Blood-based biomarkers of microvascular pathology in Alzheimer’s disease , 2010, Experimental Gerontology.

[16]  Richard L. Sprott,et al.  Biomarkers of aging and disease: Introduction and definitions , 2010, Experimental Gerontology.

[17]  J. Trojanowski,et al.  Total and phosphorylated tau protein as biological markers of Alzheimer’s disease , 2010, Experimental Gerontology.

[18]  Michael Fu,et al.  B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia , 2009, Neuroreport.

[19]  G. Siciliano,et al.  The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects. , 2009, Current Alzheimer research.

[20]  M. Horie,et al.  Plasma NT-proBNP as a more reliable biomarker of endogenous cardiac natriuretic peptides than BNP during carperitide infusion. , 2009, International heart journal.

[21]  G. Binetti,et al.  Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment , 2008, Journal of Neural Transmission.

[22]  S. Pelech.  Biomarker identification for diagnosis of Alzheimer's disease. , 2008, Expert opinion on medical diagnostics.

[23]  P. Lewczuk,et al.  Neurochemical dementia diagnostics: State of the art and research perspectives , 2008, Proteomics.

[24]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[25]  Ulrich Meier,et al.  A note on the power of Fisher's least significant difference procedure , 2006, Pharmaceutical statistics.

[26]  B. Borroni,et al.  Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful? , 2006, European journal of pharmacology.

[27]  C. Bergerot,et al.  Plasma BNP and NT-proBNP assays by automated immunoanalyzers: analytical and clinical study. , 2006, Annals of clinical and laboratory science.

[28]  A. Bayés‐Genís.  Plasma NT-proBNP: a new biomarker for diagnosis and monitoring of congestive heart failure (CHF). , 2006, Timely topics in medicine. Cardiovascular diseases.

[29]  L. Gustafson,et al.  Plasma Homocysteine and Vascular Disease in Psychogeriatric Patients , 2006, Dementia and Geriatric Cognitive Disorders.

[30]  T. Pirttilä,et al.  Problems Associated with Biological Markers of Alzheimer’s Disease , 2005, Neurochemical Research.

[31]  H. Hinterhuber,et al.  Measurement of Thirteen Biological Markers in CSF of Patients with Alzheimer’s Disease and Other Dementias , 2005, Dementia and Geriatric Cognitive Disorders.

[32]  G. Bitan,et al.  En route to early diagnosis of Alzheimer's disease--are we there yet? , 2005, Trends in biotechnology.

[33]  K. Blennow.  CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment , 2005, Expert review of molecular diagnostics.

[34]  Berislav V. Zlokovic,et al.  Neurovascular mechanisms of Alzheimer's neurodegeneration , 2005, Trends in Neurosciences.

[35]  J. Morris,et al.  Neuropathologic Criteria for Diagnosing Alzheimer Disease in Persons with Pure Dementia of Alzheimer Type , 2004, Journal of neuropathology and experimental neurology.

[36]  C. Iadecola.  Neurovascular regulation in the normal brain and in Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[37]  M. Luca,et al.  Peripheral Blood Abnormalities in Alzheimer Disease: Evidence for Early Endothelial Dysfunction , 2002, Alzheimer disease and associated disorders.

[38]  J. C. Torre,et al.  Alzheimer Disease as a Vascular Disorder: Nosological Evidence , 2002 .

[39]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[40]  J. Venugopal.  Cardiac natriuretic peptides – hope or hype? , 2001, Journal of clinical pharmacy and therapeutics.

[41]  K. Liestøl,et al.  Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. , 2000, European heart journal.

[42]  T. Kudo,et al.  Are cerebrovascular factors involved in Alzheimer’s disease? , 2000, Neurobiology of Aging.

[43]  J. Grafman,et al.  Clock Drawing in Alzheimer's Disease , 1989, Journal of the American Geriatrics Society.

[44]  J. Shaffer.  Modified Sequentially Rejective Multiple Test Procedures , 1986 .

[45]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[46]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[47]  M. Kroll,et al.  The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. , 2010, American journal of clinical pathology.

[48]  V. Henderson,et al.  Diagnosis and Treatment of Alzheimer's Disease , 2005 .

[49]  K. Jellinger.  Is Alzheimer's disease a vascular disorder? , 2003, Journal of Alzheimer's disease : JAD.

[50]  A. Drzezga,et al.  The role of biological markers in the early and differential diagnosis of Alzheimer's disease. , 2002, Journal of neural transmission. Supplementum.

[51]  K. Mattila,et al.  Two-dimensional analysis of qualitative and quantitative changes in blood cell proteins in Alzheimer's disease: search for extraneuronal markers. , 1995, Applied and theoretical electrophoresis : the official journal of the International Electrophoresis Society.

[52]  V. Leirer,et al.  Development and validation of a geriatric depression screening scale: a preliminary report. , 1982, Journal of psychiatric research.

[53]  H. Cross,et al.  The mast syndrome. A recessively inherited form of presenile dementia with motor disturbances. , 1967, Archives of neurology.